EHS
EHS

Aldeyra completes patient dosing in phase 2b trial of topical ocular reproxalap

The final patient has been dosed in a phase 2b clinical trial of topical ocular reproxalap for dry eye disease, Aldeyra Therapeutics announced in a press release.
The randomized, double-masked, vehicle-controlled, multicenter, parallel-group trial evaluated two concentrations of topical ocular reproxalap, 0.1% and 0.25%, against vehicle for 12 weeks in 300 patients with dry eye disease, the release said.
The objective of the trial is to determine a drug concentration and the appropriate number of patients for phase 3 testing.
Results from the phase 2b trial are expected in the second half of the
EHS
Back to top button